Low-level red-light therapy as a novel modality for myopia control in children: A systematic review

Keywords: myopia control, low-level red-light therapy, children


Background Due to the COVID-19 pandemic causing a rise in digital technology use, online e-learning, and decreased outdoor time, the prevalence of myopia is expected to increase. Therefore, finding an effective strategy for myopia progression control is of high importance. Low-level red-light therapy (LLRT) has been proposed as a new modality in myopia progression control.  

Objective To assess the efficacy of LLRT for myopia control in children.

Methods A comprehensive literature search of four online databases (PubMed, Cochrane, ProQuest, and WorldCat) was performed. We included original studies that assessed the efficacy of LLRT for myopia control in children and excluded animal studies, case reports, articles with no full-text available, and articles not in English. Risk of bias assessment was performed using different tools according to the study type. The main outcome measurements were changes in axial length (AL) and spherical equivalent refraction (SER).

Results Three clinical studies, two randomized controlled trials and one retrospective cohort study, were reviewed. A total of 296 children in the treatment group were evaluated. Children using single-vision spectacle only or orthokeratology lenses were evaluated for comparison. All studies had reported significantly improved outcomes, with lower mean AL changes and greater SER improvement in the LLRT group compared to the control group (P<0.001 in all studies).

Conclusion Although studies on LLRT are still limited, the treatment has shown promising results for myopia control in children. More studies to evaluate the efficacy of this new strategy are needed.


1. Wu PC, Huang HM, Yu HJ, Fang PC, Chen CT. Epidemiology of myopia. Asia Pac J Ophthalmol. 2016;5:386–93. DOI: https://doi.org/10.1097/APO.0000000000000236
2. Jiang Y, Zhu Z, Tan X, Kong X, Zhong H, Zhang J, et al. Effect of repeated low-level red-light therapy for myopia control in children: a multicenter randomized controlled trial. Ophthalmology. 2022;129:509-19. DOI: https://doi.org/10.1016/j.ophtha.2021.11.023
3. Xiong F, Mao T, Liao H, Hu X, Shang L, Yu L, et al. Orthokeratology and low-intensity laser therapy for slowing the progression of myopia in children. Biomed Res Int. 2021;2021:8915867. DOI: https://doi.org/10.1155/2021/8915867
4. Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123:1036–42. DOI: https://doi.org/10.1016/j.ophtha.2016.01.006
5. Zhou L, Xing C, Qiang W, Hua C, Tong L. Low?intensity, long?wavelength red light slows the progression of myopia in children: an Eastern China?based cohort. Ophthalmic Physiol Opt. 2022;42:335–44. DOI: https://doi.org/10.1111/opo.12939
6. Wong CW, Tsai A, Jonas JB, Ohno-Matsui K, Chen J, Ang M, et al. Digital screen time during the COVID-19 pandemic: risk for a further myopia boom? Am J Ophthalmol. 2021;223:333–7. DOI: https://doi.org/10.1016/j.ajo.2020.07.034
7. Zhang X, Cheung SSL, Chan HN, Zhang Y, Wang YM, Yip BH, et al. Myopia incidence and lifestyle changes among school children during the COVID-19 pandemic: a population-based prospective study. Br J Ophthalmol. 2022;106:1772-8. DOI: https://doi.org/10.1136/bjophthalmol-2021-319307
8. Aslan F, Sahinoglu-Keskek N. The effect of home education on myopia progression in children during the COVID-19 pandemic. Eye. 2022;36:1427–32. DOI: https://doi.org/10.1038/s41433-021-01655-2
9. Wang J, Li Y, Musch DC, Wei N, Qi X, Ding G, et al. Progression of myopia in school-aged children after COVID-19 home confinement. JAMA Ophthalmol. 2021;139:293–300. DOI: https://doi.org/10.1001/jamaophthalmol.2020.6239
10. Bullimore MA, Johnson LA. Overnight orthokeratology. Cont Lens Anterior Eye. 2020;43:322–32. DOI: https://doi.org/10.1016/j.clae.2020.03.018
11. Tong L, Huang XL, Koh ALT, Zhang X, Tan DTH, Chua WH. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Ophthalmology. 2009;116:572–9. DOI: https://doi.org/10.1016/j.ophtha.2008.10.020
12. Chen CW, Yao JY. Efficacy and adverse effects of atropine for myopia control in children: a meta-analysis of randomised controlled trials. J Ophthalmol. 2021;2021:4274572. DOI: https://doi.org/10.1155/2021/4274572
13. Johnson&Johnson Vision. Johnson & Johnson Vision Announces FDA Approval of ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management [press release]. Florida: Johnson&Johnson Vision [Internet]; 2021 May 12 [cited 2022 Jun 19]. Available from: https://www.jjvision.com/contact-us.
14. Morgan PB, Efron N, Woods CA, Santodomingo-Rubido J. International survey of orthokeratology contact lens fitting. Cont Lens Anterior Eye. 2019;42:450–4. DOI: https://doi.org/10.1016/j.clae.2018.11.005
15. Kong Q, Guo J, Zhou J, Zhang Y, Dou X. Factors determining effective orthokeratology treatment for controlling juvenile myopia progression. Iran J Public Health. 2017;46:1217–22. PMID: 29026787.
16. Liu YM, Xie P. The safety of orthokeratology - a systematic review. Eye Contact Lens. 2016;42:35–42. DOI: https://doi.org/10.1097/ICL.0000000000000219
17. Cho P, Cheung SW. Discontinuation of orthokeratology on eyeball elongation (DOEE). Cont Lens Anterior Eye. 2017;40:82–7. DOI: https://doi.org/10.1016/j.clae.2016.12.002
18. Xiong S, Sankaridurg P, Naduvilath T, Zang J, Zou H, Zhu J, et al. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017;95:551–66. DOI: https://doi.org/10.1111/aos.13403
19. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI: https://doi.org/10.1136/bmj.n71
20. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. DOI: https://doi.org/10.1186/s13643-016-0384-4
21. Sterne JAC, Savovi? J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:4898. DOI: https://doi.org/10.1136/bmj.l4898
22. Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. 2013. [cited 2022 May 10]. Available from: https://www.ohri.ca//programs/clinical_epidemiology/oxford.asp.
23. Rojas JC, Gonzalez-Lima F. Low-level light therapy of the eye and brain. Eye Brain. 2011;14:49-67. DOI: https://doi.org/10.2147/EB.S21391. PMID: 28539775; PMCID: PMC5436183.
24. Zhu Q, Xiao S, Hua Z, Yang D, Hu M, Zhu YT, et al. Near infrared (NIR) light therapy of eye diseases: a review. Int J Med Sci. 2021;18:109–19. DOI: https://doi.org/10.7150/ijms.52980
25. Walski T, D?browska K, Drohomirecka A, J?druchniewicz N, Trochanowska-Pauk N, Witkiewicz W, et al. The effect of red-to-near-infrared (R/NIR) irradiation on inflammatory processes. Int J Radiat Biol. 2019;95:1326–36. DOI: https://doi.org/10.1080/09553002.2019.1625464
26. Wu H, Chen W, Zhao F, Zhou Q, Reinach PS, Deng L, et al. Scleral hypoxia is a target for myopia control. Proc Natl Acad Sci U S A. 2018;115:E7091–100. DOI: https://doi.org/10.1073/pnas.1721443115
27. Metlapally R, Wildsoet CF. Scleral mechanisms underlying ocular growth and myopia. Prog Mol Biol Transl Sci. 2015;134:241-8. DOI: https://doi.org/10.1016/bs.pmbts.2015.05.005
28. Yuan J, Wu S, Wang Y, Pan S, Wang P, Cheng L. Inflammatory cytokines in highly myopic eyes. Sci Rep. 2019;9:3517. DOI: https://doi.org/10.1038/s41598-019-39652-x
29. Walline JJ, Lindsley KB, Vedula SS, Cotter SA, Mutti DO, Ng SM, et al. Interventions to slow progression of myopia in children. Cochrane Database Syst Rev. 2020;1:CD004916. DOI: https://doi.org/10.1002/14651858.CD004916.pub4
30. Smith EL, Hung LF, Arumugam B, Holden BA, Neitz M, Neitz J. Effects of long-wavelength lighting on refractive development in infant rhesus monkeys. Invest Ophthalmol Vis Sci. 2015;56:6490–500. DOI: https://doi.org/10.1167/iovs.15-17025
31. Gawne TJ, Ward AH, Norton TT. Long-wavelength (red) light produces hyperopia in juvenile and adolescent tree shrews. Vision Res. 2017;140:55-65. DOI: https://doi.org/10.1016/j.visres.2017.07.011
32. Jiang L, Zhang S, Schaeffel F, Xiong S, Zheng Y, Zhou X, et al. Interactions of chromatic and lens-induced defocus during visual control of eye growth in guinea pigs (Cavia porcellus). Vision Res. 2014;94:24–32. DOI: https://doi.org/10.1016/j.visres.2013.10.020
33. Strickland R, Landis EG, Pardue MT. Short-wavelength (violet) light protects mice from myopia through cone signaling. Investig Ophthalmol Vis Sci. 2020;61:13. DOI: https://doi.org/10.1167/iovs.61.2.13.
34. Wang M, Schaeffel F, Jiang B, Feldkaemper M. Effects of light of different spectral composition on refractive development and retinal dopamine in chicks. Invest Ophthalmol Vis Sci. 2018;59:4413–24. DOI: https://doi.org/10.1167/iovs.18-23880
35. Torii H, Kurihara T, Seko Y, Negishi K, Ohnuma K, Inaba T, et al. Violet light exposure can be a preventive strategy against myopia progression. EBioMedicine. 2017;15:210–9. DOI: https://doi.org/10.1016/j.ebiom.2016.12.007
How to Cite
Dewi AC, Budihardja BM, Jutamulia J. Low-level red-light therapy as a novel modality for myopia control in children: A systematic review. PI [Internet]. 22Feb.2024 [cited 18Apr.2024];64(1):28-5. Available from: https://paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/3231
Review Article
Received 2022-11-05
Accepted 2024-02-22
Published 2024-02-22